secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001711279-25-000065
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech doses first patient in Phase 1/2 trial of KB801 for neurotrophic keratitis
--------------------------------------------------------------------------------

- First patient dosed in Phase 1/2 EMERALD-1 trial of KB801, a redosable eye-drop gene therapy for neurotrophic keratitis.
- Study enrolls up to 27 adults with Stage 2 or 3 NK; 2:1 randomized to KB801 or placebo twice weekly for 8 weeks.
- Primary endpoint: safety/tolerability; secondary: complete durable corneal healing at week 8.
- NK diagnosed claims in US rose 115% from ~31,000 (2020) to ~68,000 (2024), per claims data.
- Investor call/webcast July 9 at 8:30am ET to discuss KB801 program and trial design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000065/0001711279-25-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000065/krys-20250709.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer